Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Code of Conduct [a]
CC transcript
EyePoint Pharmaceuticals, Inc. (EYPT) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/25/2021 GN EyePoint Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
02/04/2021 GN EyePoint Pharmaceuticals Announces Closing of $115 Million Public Offering of Common Stock
02/01/2021 GN EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock
01/28/2021 GN EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD
01/11/2021 GN EyePoint Pharmaceuticals Provides Business Update and Preliminary Fourth Quarter and Full-Year 2020 Net Product Revenues
01/03/2021 GN EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics
12/08/2020 GN EyePoint Pharmaceuticals Announces 1-for-10 Reverse Stock Split
12/03/2020 GN EyePoint Pharmaceuticals Reports Positive Results from GLP Toxicology Study of EYP-1901, a Potential Six-month Treatment of Wet Age-related Macular Degeneration
11/19/2020 GN EyePoint Pharmaceuticals to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD on December 4
11/10/2020 GN EyePoint Pharmaceuticals Announces Presentations at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting
10/08/2020 GN EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility Modifying 2020 and 2021 Revenue Covenants
08/24/2020 GN EyePoint Pharmaceuticals Secures New Purchase and Marketing Agreement with Vantage Outsourcing for DEXYCU®
08/20/2020 GN EyePoint Pharmaceuticals Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics Under Expanded License Agreements
07/29/2020 GN EyePoint Pharmaceuticals Announces Second Quarter 2020 Financial Results Release Date and Conference Call Information
07/27/2020 GN EyePoint Pharmaceuticals Presents Data Supporting YUTIQ?? at the American Society of Retina Specialists (ASRS) Virtual Annual Meeting
05/18/2020 GN EyePoint Pharmaceuticals Presents Data Showcasing DEXYCU® at the American Society of Cataract and Refractive Surgery 2020 Virtual Annual Meeting
04/29/2020 GN EyePoint Pharmaceuticals Announces First Quarter 2020 Financial Results Release Date and Conference Call Information
04/01/2020 GN EyePoint Pharmaceuticals Provides COVID-19 Pandemic Business Operations Update
02/21/2020 GN EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock
02/20/2020 GN EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
12/04/2019 GN EyePoint Pharmaceuticals Announces New Agreement for Expanded Access of DEXYCU® Within One of the Largest Integrated Delivery Systems in the U.S.
11/19/2019 GN EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility
11/04/2019 GN EyePoint Pharmaceuticals Announces Addition of DEXYCU® and YUTIQ® to Department of Veteran Affairs Federal Supply Schedule
10/24/2019 GN EyePoint Pharmaceuticals Announces Third Quarter 2019 Financial Results Release Date and Conference Call Information
10/02/2019 GN EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for YUTIQ® Now in Effect
09/27/2019 GN EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting
09/26/2019 GN EyePoint Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
09/09/2019 GN EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting
08/07/2019 GN EyePoint Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress
07/30/2019 GN EyePoint Pharmaceuticals Presents Positive Data Showcasing YUTIQ® at the 37th Annual Scientific Meeting of the American Society of Retina Specialists
07/25/2019 GN EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code J7314 for YUTIQ® by the Center for Medicare and Medicaid Services (CMS)
07/15/2019 GN EyePoint Pharmaceuticals Appoints Wendy DiCicco, CPA, to Board of Directors
07/01/2019 GN EyePoint Pharmaceuticals Added to Russell 3000® and 2000® Indexes
06/13/2019 GN EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy